Clinical trials: Neoplasm, Brain
Melanoma and Brain Metastases
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
This is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma that has metastasized to the brain.
- Trial name
- NCT02039947
- Testing
- Dabrafenib, Trametinib
- Where
- 47 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Adult Grade I Meningioma, Adult Grade II Meningioma
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent meningioma. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
- Conditions
- Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Meningeal Hemangiopericytoma
- Trial name
- NCT00045734
- Testing
- imatinib mesylate, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Brain Tumor, Primary
A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors
This is a pilot study to assess the changes in white matter, in the brain, in response to radiation therapy and correlate these changes with later declines in cognitive function.
- Trial name
- NCT02006407
- Testing
- Cranial Radiotherapy, MRI with Diffusion Tensor Imaging (DTI), Neuro-cognitive Testing (CogState)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan Rogel Cancer Center
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioblastoma Multiforme
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00892177
- Testing
- bevacizumab, dasatinib
- Where
- 305 sites in United States
- Volunteers
- 144 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
This early phase I trial studies how well hyperpolarized carbon C 13 pyruvate magnetic resonance imaging works in detecting lactate and bicarbonate in participants with central nervous system tumors.
- Trial name
- NCT03565367
- Testing
- Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Daniel M. Spielman
Brain Cancer
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
The goal of this clinical research study is to learn if TPI 287 can help to control glioblastoma. The safety of this drug will also be studied.
- Trial name
- NCT01113463
- Testing
- TPI 287
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan hydrochloride in treating younger patients with solid tumors that have come back (relapsed) or that have not responded to standard therapy…
- Conditions
- Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Trial name
- NCT02095132
- Testing
- Adavosertib, Irinotecan Hydrochloride
- Where
- 24 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic Stem Cell Transplantation, Cognitive Impairments
The "Light for the Brain" Study
Cognitive impairment (such as memory problems) due to cancer and its treatment can interfere with quality of life and can linger long after treatment has ended, yet research examining cognitive rehabilitation approaches has…
- Conditions
- Hematopoietic Stem Cell Transplantation, Cognitive Impairments, Sleep, Depression
- Trial name
- NCT02677987
- Testing
- Intervention systematic light exposure, Comparison systematic light exposure
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Northwestern University
Amyloidosis
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
The drugs dexamethasone and bortezomib are both FDA-approved for the treatment of multiple myeloma, a disease very similar to amyloidosis. However, they are currently investigational for the treatment of amyloidosis.
- Trial name
- NCT01083316
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Boston Medical Center
Brain Tumor, Primary
Perampanel in Seizure Patients With Primary Glial Brain Tumors
This is a Phase 2 single-arm study to assess the efficacy of perampanel as an adjunctive anti-epileptic drug (AED) in patients with primary glioma that are presenting refractory partial onset seizure activity (defined as 3 or…
- Trial name
- NCT02363933
- Testing
- Perampanel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Duke University
Primary Brain Tumor
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
The purpose of this study is to demonstrate non-inferiority of Dotarem®-enhanced MRI as compared to Gadovist®/ Gadavist®-enhanced MRI in the diagnosis of brain tumors in terms of overall lesion visualization and characterization…
- Trial name
- REMIND (NCT02034708)
- Testing
- Dotarem®, Gadovist®/Gadavist®
- Where
- 32 sites in United States, Colombia and 2 more
- Volunteers
- 279 people
- Sponsor
- Guerbet
Central Nervous System Lymphoma, Malignant Glioma
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer…
- Conditions
- Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT00103038
- Testing
- 3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- OHSU Knight Cancer Institute
Brain Neoplasms
Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation
Combidex (ferumoxtran-10) is an ultra-small iron oxide particle covered with a sugar coating. It has been evaluated as an MRI contrast agent for use in imaging well perfused organs such as the liver and spleen and for imaging…
- Trial name
- NCT00659334
- Testing
- Ferumoxtran-10 (Combidex), Neurosurgery
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- OHSU Knight Cancer Institute
Brain Tumor
Multihance at 3 Tesla (3T) in Brain Tumors
Compare the efficacy of MultiHance and Magnevist
- Trial name
- NCT00395863
- Testing
- Multihance, Arm 2 - Magnevist
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Bracco Diagnostics, Inc
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving stereotactic radiosurgery after surgery may kill any tumor cells that remain after surgery.
- Trial name
- NCT00814463
- Testing
- MMSE, QOL via FACT-Br, MRI
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Melanoma and Brain Metastases
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma…
- Trial name
- Break MB (NCT01266967)
- Testing
- GSK2118436
- Where
- 24 sites in United States, Australia and 4 more
- Volunteers
- 172 people
- Sponsor
- GlaxoSmithKline
Brain and Central Nervous System Tumors
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114140
- Testing
- Temozolomide, Radiation therapy
- Where
- 47 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Radiation Therapy Oncology Group
Acromegaly, Neuroendocrine Tumors
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid…
- Trial name
- NCT02299089
- Testing
- octreotide FluidCrystal® injection depot
- Where
- 10 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Camurus AB